FDA Approves Generic Medication for Muscle Relaxation, Tracheal Intubation


The new product is therapeutically equivalent to Pfizer’s Quelicin.

Amphastar Pharmaceuticals has received FDA approval for succinylcholine chloride injection USP, 200 mg/10mL multiple-dose vials as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

The new product is therapeutically equivalent to Pfizer’s Quelicin. According to Amphastar, IQVIA data showed that succinylocholine chloride injection USP, 200 mg/10 mL made approximately $75 million in United States market annual sales for the 12 months prior to March 31, 2020.


Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial [news release]. Amphastar Pharmaceuticals; June 9, 2020. http://ir.amphastar.com/news-releases/news-release-details/amphastar-pharmaceuticals-inc-receives-fda-approval. Accessed June 9, 2020.

Related Videos
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Pharmacist holding medicine box and capsule pack in pharmacy drugstore. -- Image credit: I Viewfinder | stock.adobe.com
Image credit: Goffkein | stock.adobe.com
Image credit: Wild Awake | stock.adobe.com
Image credit: Dglimages | stock.adobe.com
Pharmacists checking inventory at pharmacy -- Image credit: Jacob Lund | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.